All Stories

  1. Supplementary Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Article • December 2025, American Association for Cancer Research (AACR)

    Samuli Eldfors

  2. Supplementary Figures from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Article • December 2025, American Association for Cancer Research (AACR)

    Samuli Eldfors

  3. Supplementary Tables from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Article • December 2025, American Association for Cancer Research (AACR)

    Samuli Eldfors

  4. Sensitivity to ATR-CHK1 pathway inhibition in AML/MDS is enhanced by SRSF2 mutations and reduced by RUNX1 loss

    Article • October 2025, Cold Spring Harbor Laboratory Press

    Samuli Eldfors

  5. Whole Exome Sequencing and Single-Cell DNA Sequencing for Assessment of Clonal Heterogeneity and Evolution in Acute Myeloid Leukemia

    Article • June 2025, Cold Spring Harbor Laboratory Press

    Samuli Eldfors

  6. Monosomy 7/del(7q) Cause Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

    Article • Blood Advances, January 2024, American Society of Hematology

    Samuli Eldfors

  7. P-374 Stratifying multiple myeloma patients for personalized therapy based on TP53 mutation, deletion, and drug response profiles

    Article • Clinical Lymphoma Myeloma & Leukemia, September 2023, Elsevier

    Samuli Eldfors

  8. Monosomy 7/del(7q) Cause Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

    Article • April 2023, Cold Spring Harbor Laboratory Press

    Samuli Eldfors

  9. Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Article • April 2023, American Association for Cancer Research (AACR)

    Samuli Eldfors

  10. Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Article • April 2023, American Association for Cancer Research (AACR)

    Samuli Eldfors

  11. Supplementary Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Article • April 2023, American Association for Cancer Research (AACR)

    Samuli Eldfors

  12. Supplementary Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Article • April 2023, American Association for Cancer Research (AACR)

    Samuli Eldfors

  13. Supplementary Figures from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Article • April 2023, American Association for Cancer Research (AACR)

    Samuli Eldfors

  14. Supplementary Figures from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Article • April 2023, American Association for Cancer Research (AACR)

    Samuli Eldfors

  15. Supplementary Tables from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Article • April 2023, American Association for Cancer Research (AACR)

    Samuli Eldfors

  16. Supplementary Tables from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

    Article • April 2023, American Association for Cancer Research (AACR)

    Samuli Eldfors

  17. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia

    Article • Blood, March 2023, American Society of Hematology

    Samuli Eldfors

  18. Implementing a functional precision medicine tumor board for acute myeloid leukemia

    Article • Cancer Discovery, November 2021, American Association for Cancer Research (AACR)

    Samuli Eldfors

  19. Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature

    Article • Frontiers in Immunology, November 2020, Frontiers

    Samuli Eldfors

  20. Converging molecular evolution in acute myeloid leukaemia

    Article • November 2020, Cold Spring Harbor Laboratory Press

    Samuli Eldfors

  21. Molecular Basis of Mismatch Repair Protein Deficiency in Tumors from Lynch Suspected Cases with Negative Germline Test Results

    Article • Cancers, July 2020, MDPI AG

    Samuli Eldfors

  22. Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease

    Article • Nature Communications, May 2020, Springer Science + Business Media

    Samuli Eldfors

  23. Does breast carcinoma belong to the Lynch syndrome tumor spectrum? – Somatic mutational profiles vs. ovarian and colorectal carcinomas

    Article • Oncotarget, April 2020, Impact Journals, LLC

    Samuli Eldfors

  24. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia

    Article • Blood Advances, February 2020, American Society of Hematology

    Samuli Eldfors

  25. Somatic mutations and T-cell clonality in patients with immunodeficiency

    Article • Haematologica, December 2019, Ferrata Storti Foundation (Haematologica)

    Samuli Eldfors

  26. Somatic Mutations in Clonally Expanded T-lymphocytes in Patients with Chronic Graft-Versus-Host Disease

    Article • August 2019, Cold Spring Harbor Laboratory Press

    Samuli Eldfors

  27. Abstract 2945: Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling

    Article • July 2019, American Association for Cancer Research (AACR)

    Samuli Eldfors

  28. Epidemiological, clinical and molecular characterization of Lynch‐like syndrome: A population‐based study

    Article • International Journal of Cancer, January 2019, Wiley

    Samuli Eldfors

  29. Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia

    Article • Leukemia, December 2018, Springer Science + Business Media

    Samuli Eldfors

  30. Somatic Mutations in CD8+ T Cells in Patients with Chronic Immune Thrombocytopenia Are Associated with Increased Clonality and Cytotoxic Phenotype of CD8+ T Cells

    Article • Blood, November 2018, American Society of Hematology

    Samuli Eldfors

  31. Somatic Mutations in T Cells As Possible Regulators of Immunodeficiency

    Article • Blood, November 2018, American Society of Hematology

    Samuli Eldfors

  32. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells

    Article • International Journal of Cancer, November 2018, Wiley

    Samuli Eldfors

  33. Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas

    Article • Gynecologic Oncology, July 2018, Elsevier

    Samuli Eldfors

  34. Abstract 2199: Establishment and high-throughput drug testing of multiple patient-derived cells from each renal cancer; intratumor heterogeneity of drug response and implications for precision medicine

    Article • July 2018, American Association for Cancer Research (AACR)

    Samuli Eldfors

  35. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target

    Article • Nature Communications, April 2018, Springer Science + Business Media

    Samuli Eldfors

  36. Sequencing of Lynch syndrome tumors reveals the importance of epigenetic alterations

    Article • Oncotarget, November 2017, Impact Journals, LLC

    Samuli Eldfors

  37. 3Precision systems medicine in urological Tumors – Molecular profiling and functional testing

    Article • Annals of Oncology, October 2017, Oxford University Press (OUP)

    Samuli Eldfors

  38. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling

    Article • Leukemia, August 2017, Nature

    Samuli Eldfors

  39. Abstract 410: Identifying ovarian cancer specific targeted drugs using high-throughput drug sensitivity profiles of primary cancer cells

    Article • July 2017, American Association for Cancer Research (AACR)

    Samuli Eldfors

  40. Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis

    Article • Nature Communications, June 2017, Nature

    Samuli Eldfors

  41. Identification of precision treatment strategies for relapsed/ refractory multiple myeloma by functional drug sensitivity testing

    Article • Oncotarget, May 2017, Impact Journals, LLC

    Samuli Eldfors

  42. Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer

    Article • European Urology, March 2017, Elsevier

    Prof. Tero Aittokallio, Samuli Eldfors

  43. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML

    Article • Leukemia, November 2016, Nature

    Samuli Eldfors

  44. Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia

    Article • Leukemia, October 2016, Nature

    Samuli Eldfors

  45. High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia

    Article • Blood, October 2016, American Society of Hematology

    Samuli Eldfors

  46. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia

    Article • Leukemia, August 2016, Nature

    Samuli Eldfors

  47. Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia

    Article • Leukemia, July 2016, Nature

    Samuli Eldfors

  48. Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer

    Article • BMC Cancer, July 2016, Springer Science + Business Media

    Samuli Eldfors

  49. A6.02 Somatic mutations in clonally expanded CD8+T cells in patients with newly diagnosed rheumatoid arthritis

    Article • Annals of the Rheumatic Diseases, February 2016, BMJ

    Samuli Eldfors

  50. Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers

    Article • Oncogene, January 2016, Nature

    Samuli Eldfors

  51. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia

    Article • Leukemia, September 2015, Nature

    Samuli Eldfors

  52. Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3

    Article • Blood, October 2014, American Society of Hematology

    Samuli Eldfors

  53. Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing

    Article • Experimental Dermatology, April 2014, Wiley

    Samuli Eldfors

  54. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia

    Article • Leukemia, February 2014, Nature

    Samuli Eldfors

  55. Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation

    Article • Blood Cancer Journal, December 2013, Nature

    Samuli Eldfors

  56. Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia

    Article • Cancer Discovery, September 2013, American Association for Cancer Research (AACR)

    Samuli Eldfors

  57. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia

    Article • Blood, April 2013, American Society of Hematology

    Samuli Eldfors

  58. SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, May 2012, New England Journal of Medicine (NEJM/MMS)

    Samuli Eldfors

  59. Comparison of solution-based exome capture methods for next generation sequencing

    Article • Genome Biology, January 2011, Springer Science + Business Media

    Prof Taneli Raivio, Samuli Eldfors